ROCA Test for Ovarian Cancer

A simple blood test

The ROCA Test is a blood test that determines the risk of a woman having ovarian cancer.

For postmenopausal women over 50 and women at high risk

Most ovarian cancers occur in older women, most commonly when women are over the age of 65.1 The ROCA Test is intended as a routine test for:

  • Postmenopausal women over 50 years old
  • Women between 35 and 85 years of age who are considered high risk due to family history of ovarian or breast cancer; Ashkenazi Jewish descent with a known family history of ovarian or breast cancer; or a mutation in the BRCA1 or BRCA2 or Lynch Syndrome genes

Evaluated in Major Clinical Trials

The ROCA Test has been clinically evaluated several trials, the largest of which involved over 200,000 postmenopausal women from across the UK.2, 3 More information can be found here.

Read our ROCA Test Frequently Asked Questions

Disclaimer: Interpretation of the ROCA Test results is based upon outcomes data from clinical trials. The ROCA Test can detect 85% of ovarian cancers if a patient meets the eligibility criteria listed above and when used in the same multimodal strategy as in the clinical trials. If a patient falls outside of the eligibility criteria, Abcodia cannot guarantee the test results. Any clinical assessment and determination of a course of treatment is solely the responsibility of a patient’s doctor. Abcodia does not offer or provide medical judgment. It is recommended that all ROCA Test results be reviewed by a patient with her doctor.


  1. Cancer Research UK. Last accessed January 2018.
  2. Menon U, Ryan A, Kalsi J, Gentry-Maharaj A, Dawnay A, et al. (2015) A risk algorithm using serial biomarker measurements doubles the number of screen-detected cancers compared to a single threshold rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) J Clin Oncol; Jun 20;33(18):2062-71.
  3. Jacobs IJ, Menon U, Ryan A, et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet 2016; 387: 944 –  956.